Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

Video content above is prompted by the following:

• Describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC lacking targetable driver mutations.
• What proportion of mNSCLC patients harbor drivers like EGFR, ALK, etc?
  • How does the presence of these mutations impact prognosis and guide first-line treatment?
• What are the unique challenges and unmet needs for specific subgroups of mNSCLC patients without drivers, such as those with without PD-L1 expression, squamous histology, or brain metastases?
• Beyond PD-L1, what factors do you consider when selecting first-line treatment in the driver-negative setting?